ECSP20025899A - Compuestos útiles para inhibir a cdk7 - Google Patents

Compuestos útiles para inhibir a cdk7

Info

Publication number
ECSP20025899A
ECSP20025899A ECSENADI202025899A ECDI202025899A ECSP20025899A EC SP20025899 A ECSP20025899 A EC SP20025899A EC SENADI202025899 A ECSENADI202025899 A EC SENADI202025899A EC DI202025899 A ECDI202025899 A EC DI202025899A EC SP20025899 A ECSP20025899 A EC SP20025899A
Authority
EC
Ecuador
Prior art keywords
compounds useful
inhibit cdk7
cdk7
inhibit
new
Prior art date
Application number
ECSENADI202025899A
Other languages
English (en)
Inventor
David Andrew Coates
Bharvin Kumar Rameschandra Patel
Carlos Montero
Vipin Yadav
David Michael Remick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP20025899A publication Critical patent/ECSP20025899A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a nuevos inhibidores de CDK7 y composiciones farmacéuticas de los mismos, o una sal del mismo farmacéuticamente aceptable.
ECSENADI202025899A 2017-11-16 2020-05-15 Compuestos útiles para inhibir a cdk7 ECSP20025899A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382778 2017-11-16
EP18382034 2018-01-23
EP18382546 2018-07-20

Publications (1)

Publication Number Publication Date
ECSP20025899A true ECSP20025899A (es) 2020-06-30

Family

ID=64477309

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202025899A ECSP20025899A (es) 2017-11-16 2020-05-15 Compuestos útiles para inhibir a cdk7

Country Status (33)

Country Link
US (3) US10472370B2 (es)
EP (1) EP3710446B1 (es)
JP (1) JP6633254B2 (es)
KR (1) KR102450727B1 (es)
CN (1) CN111344292B (es)
AU (1) AU2018369508B2 (es)
BR (1) BR112020008253A2 (es)
CA (1) CA3080910C (es)
CL (1) CL2020001218A1 (es)
CR (1) CR20200184A (es)
DK (1) DK3710446T3 (es)
DO (1) DOP2020000102A (es)
EC (1) ECSP20025899A (es)
ES (1) ES2925219T3 (es)
HR (1) HRP20221152T1 (es)
HU (1) HUE060078T2 (es)
IL (1) IL274540B (es)
JO (1) JOP20200122B1 (es)
LT (1) LT3710446T (es)
MD (1) MD3710446T2 (es)
MX (1) MX2020004932A (es)
MY (1) MY197700A (es)
NZ (1) NZ763551A (es)
PE (1) PE20210392A1 (es)
PH (1) PH12020550792A1 (es)
PL (1) PL3710446T3 (es)
RS (1) RS63530B1 (es)
SA (1) SA520411990B1 (es)
SG (1) SG11202003677UA (es)
SI (1) SI3710446T1 (es)
TW (1) TWI703149B (es)
UA (1) UA122893C2 (es)
WO (1) WO2019099298A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805218A1 (en) * 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
CN114901284A (zh) * 2019-10-29 2022-08-12 希洛斯医药品股份有限公司 用细胞周期蛋白依赖性激酶7(cdk7)抑制剂治疗生物标志物鉴定的患者的癌症的方法
US20230115907A1 (en) * 2019-12-20 2023-04-13 Evopoint Biosciences Co., Ltd. Heterocyclic compound and pharmaceutical composition, preparation method, intermediate and use thereof
CN114075205A (zh) * 2020-08-12 2022-02-22 隆泰申医药科技(南京)有限公司 Cdk激酶抑制剂、其制备方法、药物组合物和应用
USD1078077S1 (en) 2021-08-31 2025-06-03 MerchSource, LLC Percussion massager
USD1004119S1 (en) 2021-08-31 2023-11-07 MerchSource, LLC Percussion massager
USD1079042S1 (en) 2021-08-31 2025-06-10 MerchSource, LLC Percussion massager
USD1004118S1 (en) 2021-08-31 2023-11-07 MerchSource, LLC Percussion massager
USD1079041S1 (en) 2021-08-31 2025-06-10 MerchSource, LLC Percussion massager
USD1060711S1 (en) 2021-08-31 2025-02-04 MerchSource, LLC Percussion massager
USD1079044S1 (en) 2021-08-31 2025-06-10 MerchSource, LLC Percussion massager
USD987844S1 (en) 2021-08-31 2023-05-30 MerchSource, LLC Percussion massager
USD1051414S1 (en) 2021-08-31 2024-11-12 MerchSource, LLC Percussion massager
USD1079043S1 (en) 2021-08-31 2025-06-10 MerchSource, LLC Percussion massager
USD1004117S1 (en) 2021-08-31 2023-11-07 MerchSource, LLC Percussion massager
USD994898S1 (en) 2021-11-17 2023-08-08 MerchSource, LLC Percussion massager
USD995812S1 (en) 2021-11-22 2023-08-15 MerchSource, LLC Percussion massager
USD1018881S1 (en) 2021-12-22 2024-03-19 MerchSource, LLC Percussion massager
USD1009292S1 (en) 2021-12-22 2023-12-26 MerchSource, LLC Percussion massager
USD1004121S1 (en) 2021-12-31 2023-11-07 MerchSource, LLC Pivoting percussion massager
USD1004122S1 (en) 2021-12-31 2023-11-07 MerchSource, LLC Pivoting percussion massager
CN114452391B (zh) * 2022-01-28 2023-08-25 深圳市泰尔康生物医药科技有限公司 Cdk16作为靶标在制备用于治疗三阴性乳腺癌的药物中的应用
CA3251059A1 (en) 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems and methods for modulating a target gene
KR20250091232A (ko) * 2022-10-25 2025-06-20 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 피페리디노피리미딘계 유도체, 이의 제조 방법 및 이의 의학적 응용
WO2024125532A1 (zh) * 2022-12-12 2024-06-20 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025040170A1 (zh) * 2023-08-24 2025-02-27 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
TW202535869A (zh) 2023-10-23 2025-09-16 大陸商上海拓界生物醫藥科技有限公司 一種含有噻唑基的哌啶并嘧啶類衍生物、其製備方法及其醫藥上的應用
USD1111181S1 (en) 2024-03-19 2026-02-03 MerchSource, LLC Percussion massager
USD1111182S1 (en) 2024-03-19 2026-02-03 MerchSource, LLC Percussion massager

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60313872T2 (de) * 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3805218A1 (en) * 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3268000B1 (en) * 2015-03-09 2021-08-04 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
DK3302448T3 (da) 2015-06-04 2024-02-05 Aurigene Oncology Ltd Erstattede heterocyclylafledninger som cdk-inhibitore
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物

Also Published As

Publication number Publication date
MX2020004932A (es) 2020-08-27
SI3710446T1 (sl) 2022-09-30
UA122893C2 (uk) 2021-01-13
RS63530B1 (sr) 2022-09-30
SA520411990B1 (ar) 2022-07-24
WO2019099298A1 (en) 2019-05-23
AU2018369508A1 (en) 2020-05-07
US20190144456A1 (en) 2019-05-16
IL274540A (en) 2020-06-30
LT3710446T (lt) 2022-09-26
US10787460B2 (en) 2020-09-29
IL274540B (en) 2022-06-01
CR20200184A (es) 2020-06-01
DK3710446T3 (da) 2022-08-01
MY197700A (en) 2023-07-06
AU2018369508B2 (en) 2021-03-11
JP6633254B2 (ja) 2020-01-22
MD3710446T2 (ro) 2022-12-31
CL2020001218A1 (es) 2020-08-21
KR102450727B1 (ko) 2022-10-06
BR112020008253A2 (pt) 2020-11-17
JOP20200122B1 (ar) 2023-09-17
JOP20200122A1 (ar) 2020-05-20
EP3710446A1 (en) 2020-09-23
TWI703149B (zh) 2020-09-01
US20200017513A1 (en) 2020-01-16
ES2925219T3 (es) 2022-10-14
CN111344292A (zh) 2020-06-26
HUE060078T2 (hu) 2023-01-28
NZ763551A (en) 2021-12-24
CA3080910A1 (en) 2019-05-23
JP2019537616A (ja) 2019-12-26
CN111344292B (zh) 2022-06-03
PL3710446T3 (pl) 2022-10-10
CA3080910C (en) 2023-02-07
SG11202003677UA (en) 2020-05-28
US10472370B2 (en) 2019-11-12
DOP2020000102A (es) 2020-08-31
HRP20221152T1 (hr) 2022-11-25
PH12020550792A1 (en) 2021-04-12
KR20200070323A (ko) 2020-06-17
TW201930305A (zh) 2019-08-01
EP3710446B1 (en) 2022-07-20
PE20210392A1 (es) 2021-03-02
US20210032257A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CO2020000527A2 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
UY36275A (es) Compuestos aminopirimidinilo
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2017013797A (es) Inhibidor de janus quinasa.
ECSP17029203A (es) Inhibidor de cinasa aurora a
MX2017009449A (es) Inhibidor jak.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
DK3328843T3 (da) 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
ECSP17054980A (es) Inhibidores selectivos de bace1
CR20160538A (es) Combinación
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2016001480A (es) Formulacion de inhibidores de syk.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
SV2016005313A (es) Derivados de carboxamida
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
AR113817A1 (es) Compuestos útiles para inhibir a cdk7